A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

Inclusion Criteria: * Signed and dated informed consent form * Willing to comply with all study procedures and available for the entire duration of the study * Age between 18 and 55 years * BMI 17 - 32 kg/m2 * In good general health confirmed by medical history, physical examination, and absence of clinically important laboratory abnormalities per investigator's judgment; * Women of reproductive potential must use, between study day and the final study visit, a highly effective contraceptive, as defined in the Informed Consent Document, and have a negative urine pregnancy test at the time of screening, as well as on the day of study. Exclusion Criteria: * Unable to swallow an intact 000 capsule with water * History of gastrointestinal surgery or illness, including diarrhea, constipation or other manifestations suggestive of abnormal digestion * Use of an antacid, proton pump inhibitor or histamine H2 receptor antagonist within 5 days of study day * Barium ingestion within 30 days of study day * Allergy or sensitivity to contrast media, iodine, barium sulfate, or latex * History chronic disease other than mild to moderate systemic hypertension * Menstruation on day of dosing * Pregnancy or lactating state * Participation in an investigational or marketed drug trial within 30 days of the screening visit * Low likelihood, in the investigator's judgment, to complete the study as required per study plan; * Any other history which, in the investigator's judgment, makes the subject ineligible or exposes the subject to a risk; * History of allergic reactions to a component of the RaniPill device or any allergic history other than common food (i.e. shellfish) or insect (i.e. bees) allergies; * Febrile illness within 5 days; * History of drug or alcohol abuse or any other factor that, in the investigator's opinion, may interfere with the subject's ability to cooperate and comply with the study procedures.